- Report
- November 2025
- 198 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP
- Report
- November 2025
- 183 Pages
Global
From €4045EUR$4,500USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4036EUR$4,490USD£3,503GBP
- Report
- February 2026
- 250 Pages
Global
From €4036EUR$4,490USD£3,503GBP
- Report
- March 2026
- 373 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 282 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- June 2025
- 400 Pages
Global
From €4448EUR$4,949USD£3,862GBP
- Report
- February 2026
- 171 Pages
Global
From €4359EUR$4,850USD£3,784GBP
- Report
- April 2025
- 125 Pages
United States
From €2921EUR$3,250USD£2,536GBP
- Report
- February 2025
- 315 Pages
Global
From €4314EUR$4,799USD£3,744GBP
- Report
- January 2025
- 456 Pages
Global
From €4449EUR$4,950USD£3,862GBP
- Report
- January 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,238GBP
- Book
- August 2021
- 312 Pages
Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more
